Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

BACKGROUND: The majority of multiple sclerosis [MS] patients treated with fingolimod fail to develop a protective level of IgG humoral and adaptive cellular immune responses following full BNT162b2 SARS-CoV-2 vaccination. OBJECTIVE: To compare the efficacy of the third COVID-19 vaccine dose in vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Achiron, Anat, Mandel, Mathilda, Gurevich, Michael, Dreyer-Alster, Sapir, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Harari, Gil, Flechter, Shlomo, Falb, Rina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889521/
https://www.ncbi.nlm.nih.gov/pubmed/35235002
http://dx.doi.org/10.1007/s00415-022-11030-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889521/
https://www.ncbi.nlm.nih.gov/pubmed/35235002
http://dx.doi.org/10.1007/s00415-022-11030-0

Ejemplares similares